Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections
Eligible age
0.2–18 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. The main questions it aims to answer are: -Is TMP-SMX effective at successfully treating children with invasive infections due to MRSA? What are the side effects of TMP-SMX in children taking it for invasive infections due to MRSA? Researchers will compare TMP-SMX to a clindamycin (a commonly prescribed antibiotic for the treatment of MRSA in children) to see if TMP-SMX works better, worse or the same as clindamycin for children with invasive infections due to MRSA. Participants will: Take TMP-SMX or clindamycin for the treatment of their invasive infection due to MRSA. Will follow up with the provider treating their invasive infection at the discretion of the treating provider. Keep a diary of their symptoms and any side effects of the medicine
Sponsor: Indiana University
You may qualify if…
- ✓ 1. 60 days to 18 years of age (inclusive) at the time of oral step down treatment
- ✓ 2. Diagnosed by the clinical team with OAI or HNI:
- ✓ OAI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of OAI
- ✓ Focal finding- pain/swelling over a bone/joint, or restricted movement/failure to bear weight
- ✓ Systemic finding- fever \>38oC, or elevated c-reactive protein (CRP) or elevated erythrocyte sedimentation rate. (ESR) or elevated white blood cell count (WBC) or elevated WBC in synovial fluid OR
- ✓ Radiographic confirmation- findings consistent with osteomyelitis or septic arthritis - Plain radiograph, MRI, CT or ultrasound, bone scan result indicating abnormal bone, subperiosteal or bone marrow findings consistent with infection
- ✓ HNI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of HNI
- ✓ Focal finding- facial pain or redness, eye pain or proptosis, neck or throat pain or swelling, ear pain or proptosis
You may not qualify if…
- ✕ 1. Enrollment in another interventional study or receipt of investigational drug as part of a research trial within the past 30 days.
- ✕ 2. Known cancer, acquired or primary (including sickle cell anemia or G6PD deficiency) immunodeficiency
- ✕ 3. Underlying bone disease, presence of hardware /implantable device in affected bone/joint
- ✕ 4. Infection (OAI or HNI) resulting from penetrating wounds, open fractures, major trauma, foreign body or post-operative infection.
- ✕ 5. Spinal osteomyelitis
- ✕ 6. Underlying chronic renal, gastrointestinal, liver, or heart disease that would be expected to potentially affect absorption or the metabolism of assigned drug
- ✕ 7. Inability to take medicine by mouth, gastrostomy, jejunostomy or nasogastric tube
- ✕ 8. Received intravenous antibiotic therapy as the treatment for OAI or HNI \>14 days.
Where it's recruiting
Indianapolis
Source: ClinicalTrials.gov · NCT06982105 · last updated 2026-07-29